Single-dose versus fractionated radioimmunotherapy

Model comparisons for uniform tumor dosimetry

Joseph A. O'Donoghue, George Sgouros, Chaitanya R. Divgi, John L. Humm

Research output: Contribution to journalArticle

Abstract

Targeting molecules with reduced immunogenicity will enable repetitive administrations of radioimmunotherapy. In this work a mathematical model was used to compare 2 different treatment strategies: large single administrations (LSAs) and rapid fractionation (RF) of small individual administrations separated by short time intervals. Methods: An integrated compartmental model of treatment pharmacokinetics and tumor response was used to compare alternative treatments that delivered identical absorbed doses to red marrow. Results: Based on the key assumption of uniform dose distributions, the LSA approach consistently produced smaller nadir values of tumor cell survival and tumor size. The predicted duration of remission was similar for both treatment structures. These findings held for both macroscopic and microscopic tumors and were independent of tumor cell radiosensitivity, proliferation rate, rate of tumor shrinkage, and uptake characteristics of radiolabeled material in tumor. Conclusion: Clinical situations for which each treatment is most appropriate may be tentatively identified. An LSA using a short-range-emitting radionuclide would be most appropriate for therapy of microscopic disease, if uptake is relatively homogeneous. RF using a longer range emitter would be most appropriate for macroscopic disease, if uptake is heterogeneous and varies from one administration to another. There is a rationale for combining LSA and RF treatments in clinical situations in which slowly growing macroscopic disease and rapidly growing microscopic disease exist simultaneously.

Original languageEnglish (US)
Pages (from-to)538-547
Number of pages10
JournalJournal of Nuclear Medicine
Volume41
Issue number3
StatePublished - Mar 2000
Externally publishedYes

Fingerprint

Radioimmunotherapy
Neoplasms
Therapeutics
Radiation Tolerance
Radioisotopes
Cell Survival
Theoretical Models
Pharmacokinetics
Bone Marrow
Cell Proliferation

Keywords

  • Cure
  • Fractionation
  • Gompertzian growth
  • Mathematical model
  • Radioimmunotherapy
  • Remission
  • Tumor response

ASJC Scopus subject areas

  • Radiological and Ultrasound Technology

Cite this

Single-dose versus fractionated radioimmunotherapy : Model comparisons for uniform tumor dosimetry. / O'Donoghue, Joseph A.; Sgouros, George; Divgi, Chaitanya R.; Humm, John L.

In: Journal of Nuclear Medicine, Vol. 41, No. 3, 03.2000, p. 538-547.

Research output: Contribution to journalArticle

O'Donoghue, Joseph A. ; Sgouros, George ; Divgi, Chaitanya R. ; Humm, John L. / Single-dose versus fractionated radioimmunotherapy : Model comparisons for uniform tumor dosimetry. In: Journal of Nuclear Medicine. 2000 ; Vol. 41, No. 3. pp. 538-547.
@article{8cdb1d282eee47b68978e353ddf94397,
title = "Single-dose versus fractionated radioimmunotherapy: Model comparisons for uniform tumor dosimetry",
abstract = "Targeting molecules with reduced immunogenicity will enable repetitive administrations of radioimmunotherapy. In this work a mathematical model was used to compare 2 different treatment strategies: large single administrations (LSAs) and rapid fractionation (RF) of small individual administrations separated by short time intervals. Methods: An integrated compartmental model of treatment pharmacokinetics and tumor response was used to compare alternative treatments that delivered identical absorbed doses to red marrow. Results: Based on the key assumption of uniform dose distributions, the LSA approach consistently produced smaller nadir values of tumor cell survival and tumor size. The predicted duration of remission was similar for both treatment structures. These findings held for both macroscopic and microscopic tumors and were independent of tumor cell radiosensitivity, proliferation rate, rate of tumor shrinkage, and uptake characteristics of radiolabeled material in tumor. Conclusion: Clinical situations for which each treatment is most appropriate may be tentatively identified. An LSA using a short-range-emitting radionuclide would be most appropriate for therapy of microscopic disease, if uptake is relatively homogeneous. RF using a longer range emitter would be most appropriate for macroscopic disease, if uptake is heterogeneous and varies from one administration to another. There is a rationale for combining LSA and RF treatments in clinical situations in which slowly growing macroscopic disease and rapidly growing microscopic disease exist simultaneously.",
keywords = "Cure, Fractionation, Gompertzian growth, Mathematical model, Radioimmunotherapy, Remission, Tumor response",
author = "O'Donoghue, {Joseph A.} and George Sgouros and Divgi, {Chaitanya R.} and Humm, {John L.}",
year = "2000",
month = "3",
language = "English (US)",
volume = "41",
pages = "538--547",
journal = "Journal of Nuclear Medicine",
issn = "0161-5505",
publisher = "Society of Nuclear Medicine Inc.",
number = "3",

}

TY - JOUR

T1 - Single-dose versus fractionated radioimmunotherapy

T2 - Model comparisons for uniform tumor dosimetry

AU - O'Donoghue, Joseph A.

AU - Sgouros, George

AU - Divgi, Chaitanya R.

AU - Humm, John L.

PY - 2000/3

Y1 - 2000/3

N2 - Targeting molecules with reduced immunogenicity will enable repetitive administrations of radioimmunotherapy. In this work a mathematical model was used to compare 2 different treatment strategies: large single administrations (LSAs) and rapid fractionation (RF) of small individual administrations separated by short time intervals. Methods: An integrated compartmental model of treatment pharmacokinetics and tumor response was used to compare alternative treatments that delivered identical absorbed doses to red marrow. Results: Based on the key assumption of uniform dose distributions, the LSA approach consistently produced smaller nadir values of tumor cell survival and tumor size. The predicted duration of remission was similar for both treatment structures. These findings held for both macroscopic and microscopic tumors and were independent of tumor cell radiosensitivity, proliferation rate, rate of tumor shrinkage, and uptake characteristics of radiolabeled material in tumor. Conclusion: Clinical situations for which each treatment is most appropriate may be tentatively identified. An LSA using a short-range-emitting radionuclide would be most appropriate for therapy of microscopic disease, if uptake is relatively homogeneous. RF using a longer range emitter would be most appropriate for macroscopic disease, if uptake is heterogeneous and varies from one administration to another. There is a rationale for combining LSA and RF treatments in clinical situations in which slowly growing macroscopic disease and rapidly growing microscopic disease exist simultaneously.

AB - Targeting molecules with reduced immunogenicity will enable repetitive administrations of radioimmunotherapy. In this work a mathematical model was used to compare 2 different treatment strategies: large single administrations (LSAs) and rapid fractionation (RF) of small individual administrations separated by short time intervals. Methods: An integrated compartmental model of treatment pharmacokinetics and tumor response was used to compare alternative treatments that delivered identical absorbed doses to red marrow. Results: Based on the key assumption of uniform dose distributions, the LSA approach consistently produced smaller nadir values of tumor cell survival and tumor size. The predicted duration of remission was similar for both treatment structures. These findings held for both macroscopic and microscopic tumors and were independent of tumor cell radiosensitivity, proliferation rate, rate of tumor shrinkage, and uptake characteristics of radiolabeled material in tumor. Conclusion: Clinical situations for which each treatment is most appropriate may be tentatively identified. An LSA using a short-range-emitting radionuclide would be most appropriate for therapy of microscopic disease, if uptake is relatively homogeneous. RF using a longer range emitter would be most appropriate for macroscopic disease, if uptake is heterogeneous and varies from one administration to another. There is a rationale for combining LSA and RF treatments in clinical situations in which slowly growing macroscopic disease and rapidly growing microscopic disease exist simultaneously.

KW - Cure

KW - Fractionation

KW - Gompertzian growth

KW - Mathematical model

KW - Radioimmunotherapy

KW - Remission

KW - Tumor response

UR - http://www.scopus.com/inward/record.url?scp=0034051611&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034051611&partnerID=8YFLogxK

M3 - Article

VL - 41

SP - 538

EP - 547

JO - Journal of Nuclear Medicine

JF - Journal of Nuclear Medicine

SN - 0161-5505

IS - 3

ER -